Overall: Advocates will learn about lobular breast cancer and lobular breast cancer research. Advocates will learn different ways they can get involved in effective advocacy to advance research and educate about lobular breast disease.

Morning Sessions:
Advocates will obtain a basic knowledge of the biology, treatment and research for lobular breast cancer including:

- **Basic Science and Biology of ILC**: Discussion of how ILC differs from ductal cancers and why that matters in research particularly to identify targeted therapies. Histology, pathology, subtypes and unique metastatic sites of ILC will be discussed.
- **Treatment of ILC**: Discussion of the unique challenges in treating ILC and how research can help refine treatments. The challenges of imaging, surgery, and treatment differences in ILC including the role of chemotherapy and endocrine therapies. Treatment resistance and metastatic ILC will also be discussed.
- **Research**: Discussion of types of clinical trials, study design and scientific literature. How research develops into new therapies and the challenges lobular researchers face including: funding, collaboration and under accrual of clinical trials.

Afternoon Sessions:
Advocates will learn about different ways to become involved in lobular breast cancer advocacy

- **LBCA**: Advocates will learn about LBCA and how they can become involved in building and growing this organization
- **Breakout Sessions**: Advocates will learn ways to be involved in lobular breast cancer advocacy, including:
  - **Communications and social media**: How to effectively share your story with others to raise awareness and educate.
  - **Research advocacy**: Learn about research advocacy and if research advocacy is right for you
  - **Outreach and Education**: Learn and discuss ways to initiate outreach and education on lobular breast cancer in your community and in organizations. Working with institutions and organizations to broaden education.
- **Next steps/expectations and opportunities at the scientific sessions**